In vivo tau, amyloid, and gray matter profiles in the aging brain

Journal of Neuroscience

Volumn 36, Issue 28, 2016, Pages 7364-7374

  Sepulcre, Jorge ^a,b   Schultz, Aaron P ^b   Sabuncu, Mert ^b   Gomez Isla, Teresa ^b   Chhatwal, Jasmeer ^b   Becker, Alex ^a   Sperling, Reisa ^b   Johnson, Keith A ^a,b  

^a Division of Nuclear Medicine and Molecular Imaging   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Aging; Alzheimer s disease; Amyloid; Gray matter; Tau

Indexed keywords

AMYLOID BETA PROTEIN; FLORTAUCIPIR; PITTSBURGH COMPOUND B; TAU PROTEIN; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; ANILINE DERIVATIVE; FLUORINE; THIAZOLE DERIVATIVE;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN FUNCTION; COGNITIVE AGING; CONNECTOME; FEMALE; FUNCTIONAL NEUROIMAGING; GRAY MATTER; HUMAN; INFERIOR TEMPORAL CORTEX; MAJOR CLINICAL STUDY; MALE; MEDIAL TEMPORAL LOBE; NERVE CELL NETWORK; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN INTERACTION; VOXEL BASED MORPHOMETRY; AGING; BRAIN; BRAIN MAPPING; DIAGNOSTIC IMAGING; METABOLISM; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BRAIN; BRAIN MAPPING; FEMALE; FLUORINE RADIOISOTOPES; GRAY MATTER; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY; TAU PROTEINS; THIAZOLES;

EID: 84978917033     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.0639-16.2016     Document Type: Article

References (65)

1. Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW (1991) The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer’s disease. Cereb Cortex 1:103–116. CrossRef Medline
2. Ashburner J, Friston KJ (2000) Voxel-based morphometry—the methods. Neuroimage 11:805–821. CrossRef Medline
3. Bakkour A, Morris JC, Dickerson BC (2009) The cortical signature of prodromal AD: regional thinning predicts mild AD dementia. Neurology 72:1048–1055. CrossRef Medline
4. Becker JA, Hedden T, Carmasin J, Maye J, Rentz DM, Putcha D, Fischl B, Greve DN, Marshall GA, Salloway S, Marks D, Buckner RL, Sperling RA, Johnson KA (2011) Amyloid-beta associated cortical thinning in clinically normal elderly. Ann Neurol 69:1032–1042. CrossRef Medline
5. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 57: 289–300.
6. Braak H, Braak E (1991a) Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol 1:213–216. CrossRef Medline
7. Braak H, Braak E (1991b) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259. CrossRef Medline
8. Buckner RL (2004) Memory and executive function in aging and AD: multiple factors that cause decline and reserve factors that compensate. Neuron 44:195–208. CrossRef Medline
9. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos A, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA (2005) Molecular, structural, and functional characterization of Alzheimer’s disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 25:7709–7717. CrossRef Medline
10. Buckner RL, Sepulcre J, Talukdar T, Krienen FM, Liu H, Hedden T, Andrews- Hanna JR, Sperling RA, Johnson KA (2009) Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer’s disease. J Neurosci 29:1860–1873. CrossRef Medline
11. Chetelat G, Baron JC (2003) Early diagnosis of Alzheimer’s disease: contribution of structural neuroimaging. Neuroimage 18:525–541. CrossRef
12. Medline Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, Xia C, Shankle WR, Lerner AJ, Su MY, Elizarov A, Kolb HC (2014) Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 38:171–184. CrossRef Medline
13. Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, Arnold SE, Attems J, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Gearing M, Grinberg LT, Hof PR, Hyman BT, Jellinger K, Jicha GA, Kovacs GG, Knopman DS, et al. (2014) Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 128:755–766. CrossRef Medline
14. Dagley A, LaPoint M, Huijbers W, Hedden T, McLaren DG, Chatwal JP, Papp K V, Amariglio RE, Blacker D, Rentz DM, Johnson KA, Sperling RA, Schultz AP (2015) Harvard Aging Brain Study: dataset and accessibility. Neuroimage. Advance online publication. Retrieved May 25, 2016. doi: 10.1016/j.neuroimage.2015.03.069. CrossRef Medline
15. de Calignon A, Polydoro M, Suárez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT (2012) Propagation of tau pathology in a model of early Alzheimer’s disease. Neuron 73:685–697. CrossRef Medline
16. De Nooy W, Mrvar A, Batageli V (2005) Exploratory social network analysis with Pajek. Cambridge, UK: Cambridge UP.
17. Dickerson BC, Bakkour A, Salat DH, Feczko E, Pacheco J, Greve DN, Grodstein F, Wright CI, Blacker D, Rosas HD, Sperling RA, Atri A, Growdon JH, Hyman BT, Morris JC, Fischl B, Buckner RL (2009) The cortical signature of Alzheimer’s disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex 19: 497–510. CrossRef Medline
18. Greicius MD, Srivastava G, Reiss AL, Menon V (2004) Default-mode network activity distinguishes Alzheimer’s disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A 101:4637–4642. CrossRef Medline
19. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140:566–572. CrossRef Medline
20. Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL (1984) Alzheimer’s disease: cell-specific pathology isolates the hippocampal formation. Science 225:1168–1170. CrossRef Medline
21. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Thies B, Trojanowski JQ, Vinters HV, Montine TJ (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement 8:1–13. CrossRef Medline
22. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL, DeKosky ST (2008) Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain 131:1630–1645. CrossRef Medline
23. Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley-Whyte ET, Frosch MP, Albert MS, Hyman BT, Irizarry MC (2004) Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 62:925–931. CrossRef Medline
24. Jack CR Jr (2014) PART and SNAP. Acta Neuropathol 128:773–776. CrossRef Medline
25. Jack CR Jr, Petersen RC, O’Brien PC, Tangalos EG (1992) MR-based hippocampal volumetry in the diagnosis of Alzheimer’s disease. Neurology 42:183–188. CrossRef Medline
26. Johnson K, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, Mormino E, Chhatwal J, Amariglio R, Papp K, Marshall G, Albers M, Mauro S, Pepin L, Alverio J, Judge K, Philiossaint M, Shoup T, Yokell D, Dickerson B, Gomez-Isla T, Hyman B, Vasdev N, Sperling R (2016) Tau PET imaging in aging and early Alzheimer’s disease. Ann Neurol 79:110–119. CrossRef Medline
27. Johnson KA, Fox NC, Sperling RA, Klunk WE (2012) Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med 2:a006213. CrossRef Medline
28. Kalus P, Braak H, Braak E, Bohl J (1989) The presubicular region in Alzheimer’s disease: topography of amyloid deposits and neurofibrillary changes. Brain Res 494:198–203.
29. Medline Kamada T, Kawai S (1989) An algorithm for drawing general undirected graphs. Inf Process Lett 31:7–15.
30. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Långström B (2004) Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 55:306–319. CrossRef Medline
31. Kuchibhotla KV, Wegmann S, Kopeikina KJ, Hawkes J, Rudinskiy N, Andermann ML, Spires-Jones TL, Bacskai BJ, Hyman BT (2014) Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo. Proc Natl Acad Sci U S A 111:510–514. CrossRef Medline
32. Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, MacGregor RR, Hitzemann R, Bendriem B, Gatley SJ (1990) Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(_)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10:740–747.
33. Medline Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, Meltzer CC, Schimmel K, Tsopelas ND, DeKosky ST, Price JC (2005) Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 46:1959–1972.
34. Medline Marquié M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG, Klunk WE, Mathis CA, Ikonomovic MD, Debnath ML, Vasdev N, Dickerson BC, Gomperts SN, Growdon JH, Johnson KA, Frosch MP, Hyman BT, Go´ mez-Isla T (2015) Validating novel tau PET tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 78:787–800. CrossRef Medline
35. Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, Zhang MR, Trojanowski JQ, Lee VM, Ono M, Masamoto K, Takano H, Sahara N, Iwata N, Okamura N, Furumoto S, Kudo Y, Chang Q, Saido TC, Takashima A, Lewis J, Jang MK, Aoki I, Ito H, Higuchi M (2013) Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79:1094–1108. CrossRef Medline
36. Masdeu JC, Kreisl WC, Berman KF (2012) The neurobiology of Alzheimer disease defined by neuroimaging. Curr Opin Neurol 25:410–420. CrossRef Medline
37. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE (2003) Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 46:2740–2754. CrossRef Medline
38. Mattson MP (2004) Pathways towards and away from Alzheimer’s disease. Nature 430:631–639. CrossRef Medline
39. Medina M, Avila J (2014) The role of extracellular Tau in the spreading of neurofibrillary pathology. Front Cell Neurosci 8:113. CrossRef Medline
40. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE (1997) Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol 42:85–94. CrossRef Medline
41. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC (2006) [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67:446–452. CrossRef Medline
42. Mungas D, Tractenberg R, Schneider JA, Crane PK, Bennett DA (2014) A 2-process model for neuropathology of Alzheimer’s disease. Neurobiol Aging 35:301–308. CrossRef Medline
43. Ogomori K, Kitamoto T, Tateishi J, Sato Y, Suetsugu M, Abe M (1989) Beta-protein amyloid is widely distributed in the central nervous system of patients with Alzheimer’s disease. Am J Pathol 134:243–251.
44. Medline Okamura N, Furumoto S, Harada R, Tago T, Yoshikawa T, Fodero-Tavoletti M, Mulligan RS, Villemagne V, Akatsu H, Yamamoto T, Arai H, Iwata R, Yanai K, Kudo Y (2013) Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med 54:1420–1427. CrossRef Medline
45. Pearson RC, Powell TP (1989) The neuroanatomy of Alzheimer’s disease. Rev Neurosci 2:101–122. CrossRef Medline
46. Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol 45:358–368.
47. Medline Raj A, Kuceyeski A, WeinerM (2012) A network diffusion model of disease progression in dementia. Neuron 73:1204–1215. CrossRef Medline
48. Sabuncu MR, Desikan RS, Sepulcre J, Yeo BT, Liu H, Schmansky NJ, Reuter M, Weiner MW, Buckner RL, Sperling RA, Fischl B (2011) The dynamics of cortical and hippocampal atrophy in Alzheimer disease. Arch Neurol 68:1040–1048. CrossRef Medline
49. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, Kuiper M, Steinling M, Wolters EC, Valk J (1992) Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 55:967–972. CrossRef Medline
50. Schöll M, Lockhart SN, Schonhaut DR, O’Neil JP, Janabi M, Ossenkoppele R, Baker SL, Vogel JW, Faria J, Schwimmer HD, Rabinovici GD, Jagust WJ (2016) PET imaging of tau deposition in the aging human brain. Neuron 89:971–982.
51. Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD (2009) Neurodegenerative diseases target large-scale human brain networks. Neuron 62:42–52. CrossRef Medline
52. Sepulcre J, Sabuncu MR, Becker A, Sperling R, Johnson KA (2013) In vivo characterization of the early states of the amyloid-beta network. Brain 136:2239–2252. CrossRef Medline
53. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1:a006189. CrossRef Medline
54. Shoup T, Yokell D, Rice P, Jackson R, Livni E, Johnson K, Brady T, Vasdev N (2013) A concise radiosynthesis of the tau radiopharmaceutical, [(18) F]T807. J Labelled Comp Radiopharm 56:736–740. CrossRef Medline
55. Sojkova J, Driscoll I, Iacono D, Zhou Y, Codispoti KE, Kraut MA, Ferrucci L, Pletnikova O, Mathis CA, Klunk WE, O’Brien RJ, Wong DF, Troncoso JC, Resnick SM (2011) In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch Neurol 68:232–240. CrossRef Medline
56. Thal DR, Rüb U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791–1800. CrossRef Medline
57. Van Essen DC (2005) A population-average, landmark- and surfacebased (PALS) atlas of human cerebral cortex. Neuroimage 28:635–662. CrossRef Medline
58. Villain N, Fouquet M, Baron JC, Mézenge F, Landeau B, de La Sayette V, Viader F, Eustache F, Desgranges B, Chételat G (2010) Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer’s disease. Brain 133:3301–3314. CrossRef Medline
59. Villemagne VL, Pike KE, Chételat G, Ellis KA, Mulligan RS, Bourgeat P, Ackermann U, Jones G, Szoeke C, Salvado O, Martins R, O’Keefe G, Mathis CA, Klunk WE, Ames D, Masters CL, Rowe CC (2011) Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 69:181–192. CrossRef Medline
60. Villemagne VL, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Hodges J, Harada R, Yates P, Piguet O, Pejoska S, Doré V, Yanai K, Masters CL, Kudo Y, Rowe CC, Okamura N (2014) In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease. Eur J Nucl Med Mol Imaging 41:816–826. CrossRef Medline
61. Vlassenko AG, Mintun MA, Xiong C, Sheline YI, Goate AM, Benzinger TL, Morris JC (2011) Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Ann Neurol 70: 857–861. CrossRef Medline
62. Walker LC, Diamond MI, Duff KE, Hyman BT (2013) Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol 70:304–310.
63. Medline Walsh DM, Selkoe DJ (2004) Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 11: 213–228. CrossRef Medline
64. Whitwell JL, Tosakulwong N, Weigand SD, Senjem ML, Lowe VJ, Gunter JL, Boeve BF, Knopman DS, Dickerson BC, Petersen RC, Jack CR Jr. (2013) Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects? Neuroimage Clin 2:249–257. CrossRef Medline
65. Zhou J, Gennatas ED, Kramer JH, Miller BL, Seeley WW (2012) Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron 73:1216–1227. CrossRef Medline